Interpace Biosciences, Inc.
IDXGD
$6.98
-$0.02-0.29%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 124.69% | -56.22% | 1,104.52% | -45.64% | -126.26% |
| Total Depreciation and Amortization | 18.59% | 18.42% | 4.74% | 11.64% | 5.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.24% | 2,910.00% | -8,624.90% | -77.33% | 2,957.14% |
| Change in Net Operating Assets | -179.10% | -56.55% | 140.71% | 383.13% | 159.61% |
| Cash from Operations | -81.15% | -77.09% | 80.57% | -8.41% | -62.96% |
| Capital Expenditure | 71.64% | -- | 70.54% | 77.59% | -2.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 71.64% | -- | 70.54% | 77.59% | -2.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 33.33% | 40.00% | 50.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 60.87% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -- | -- | 40.36% | 40.00% | 49.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.91% | 153.58% | 265.95% | 879.79% | 12.48% |